Current and emerging pharmacotherapy for the treatment of gastroparesis

Expert Opin Pharmacother. 2024 Apr 17. doi: 10.1080/14656566.2024.2344646. Online ahead of print.ABSTRACTINTRODUCTION: Gastroparesis is a chronic disorder characterized by decreased gastric emptying and presents with nausea, vomiting, and abdominal pain which impacts patients' quality of life greatly. The treatment modalities available for gastroparesis have been expanding over the past 2 decades. Currently there are multiple options available for gastroparesis albeit with only one FDA approved medication until June of 2021.AREAS COVERED: We review the different treatments available for gastroparesis and discuss the recently FDA approved intranasal formulation of metoclopramide. This nasal spray guarantees metoclopramide absorption within 15 minutes of application bypassing first pass metabolism in the liver and overcoming the limitations of the oral formulation not passing into the small intestine for absorption because of a gastroparetic stomach or a patient unable to take the oral metoclopramide because of nausea and vomiting.EXPERT OPINION: We now find ourselves in an oasis after spending many years in a 'desert' regarding pharmacologic therapies available for gastroparesis. The expansion of the research involving dopamine receptor antagonists and delving into alternative mechanisms of alleviating gastroparesis symptoms have been crucial in the landscape of gastroparesis. This is especially true as our knowledge of gastroparesis has proved that simply improving gastric em...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research